Endogenous Human Herpesvirus: Germ line integration and effects on host cell and organism
The ENDo-HERPES project aims to investigate the functional impact of integrated HHV-6 on disease development, telomere dynamics, and host cell interactions using advanced technologies.
Projectdetails
Introduction
Endogenous viruses present in the human genome control physiological processes, modulate aging, and can cause diseases. Intriguingly, a herpesvirus has entered the human germ line by integrating its genome into telomeres of germ cells and is present in about 80 million people.
Background
The virus, human herpesvirus 6 (HHV-6), can reactivate from the integrated state, which is associated with a number of diseases. These include:
- Seizures
- Encephalitis
- Heart failure
- Graft rejection
We recently analyzed the virus genomes present in hundreds of individuals with this inherited chromosomally-integrated HHV-6 (iciHHV-6). The data show that today’s endogenous virus sequences are quite diverse and derived from dozens of independent integration events that were passed on for generations.
Knowledge Gaps
There are critical gaps in our knowledge on the functionality of iciHHV-6 genomes with respect to:
- Virus replication
- Gene expression and latency
- Its effects on the host cell
- The role of telomere shortening that occurs during aging on virus reactivation
Project Goals
ENDo-HERPES will make use of novel technology to close these gaps and provide the basis for elucidating whether diseases are associated with or caused by iciHHV-6. Specifically, we will:
- Identify which iciHHV-6 genomes are still functional and could contribute to disease development.
- Determine iciHHV-6 integration sites within the highly repetitive telomere region and assess the integration and reactivation process on the DNA level.
- Investigate the effects of the iciHHV-6 genome on host cells and if telomere shortening can induce reactivation.
Methodology
The proposal utilizes state-of-the-art technology and pioneers new approaches, particularly when investigating the integration sites of endogenous virus genomes and the mechanisms facilitating integration and reactivation.
Conclusion
Altogether, we will shed light on the life cycle and effects on the host cells of this endogenous herpesvirus present in the genome of about 1% of the human population.
Financiële details & Tijdlijn
Financiële details
Subsidiebedrag | € 2.000.000 |
Totale projectbegroting | € 2.000.000 |
Tijdlijn
Startdatum | 1-9-2023 |
Einddatum | 31-8-2028 |
Subsidiejaar | 2023 |
Partners & Locaties
Projectpartners
- FREIE UNIVERSITAET BERLINpenvoerder
Land(en)
Vergelijkbare projecten binnen European Research Council
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Interplay of CMV with cellular pathways, states and cell typesThis project aims to develop advanced tools to investigate HCMV-host interactions, uncover viral protein functions, and identify infection vulnerabilities to enhance therapeutic strategies. | ERC Consolid... | € 2.000.000 | 2025 | Details |
Deciphering cellular and viral determinants of lytic HSV-1 infection, latency and reactivationThe DecipherHSV project aims to uncover the molecular mechanisms of HSV-1 infection and latency using advanced computational tools and single-cell RNA sequencing to inform new therapeutic strategies. | ERC Consolid... | € 1.998.008 | 2022 | Details |
Endogenous Retroelements As Transcriptional Parasites And Modulators Of Host ImmunityThis project aims to explore how sporadic transcription of endogenous retroelements influences immune system priming and response to stress, potentially redefining their role in host immunity. | ERC Consolid... | € 1.999.415 | 2023 | Details |
Traitor-virus-guided discovery of antiviral factorsThis project aims to use CRISPR/Cas9 technology with HIV-1 to uncover antiviral mechanisms, enhancing our understanding and control of viral pathogens for better prevention and therapy. | ERC Advanced... | € 2.339.875 | 2022 | Details |
Investigating Virus-Host Interplay in Human Primary Models of Genetically Modified Respiratory EpitheliumThe InVIRium project aims to enhance understanding of respiratory viruses by using advanced human airway models to study antiviral defenses and viral escape mechanisms. | ERC Consolid... | € 2.475.808 | 2024 | Details |
Interplay of CMV with cellular pathways, states and cell types
This project aims to develop advanced tools to investigate HCMV-host interactions, uncover viral protein functions, and identify infection vulnerabilities to enhance therapeutic strategies.
Deciphering cellular and viral determinants of lytic HSV-1 infection, latency and reactivation
The DecipherHSV project aims to uncover the molecular mechanisms of HSV-1 infection and latency using advanced computational tools and single-cell RNA sequencing to inform new therapeutic strategies.
Endogenous Retroelements As Transcriptional Parasites And Modulators Of Host Immunity
This project aims to explore how sporadic transcription of endogenous retroelements influences immune system priming and response to stress, potentially redefining their role in host immunity.
Traitor-virus-guided discovery of antiviral factors
This project aims to use CRISPR/Cas9 technology with HIV-1 to uncover antiviral mechanisms, enhancing our understanding and control of viral pathogens for better prevention and therapy.
Investigating Virus-Host Interplay in Human Primary Models of Genetically Modified Respiratory Epithelium
The InVIRium project aims to enhance understanding of respiratory viruses by using advanced human airway models to study antiviral defenses and viral escape mechanisms.
Vergelijkbare projecten uit andere regelingen
Project | Regeling | Bedrag | Jaar | Actie |
---|---|---|---|---|
Hacking the ribosome to map virus-host associationsThe VirHoX project aims to map virus-host associations using a novel technique, VirHo-seq, to enhance understanding of viral interactions and address challenges posed by emerging pathogens. | EIC Pathfinder | € 3.000.000 | 2025 | Details |
Targeting Cancer with ERV VaccinesInProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors. | EIC Accelerator | € 2.500.000 | 2022 | Details |
Hacking the ribosome to map virus-host associations
The VirHoX project aims to map virus-host associations using a novel technique, VirHo-seq, to enhance understanding of viral interactions and address challenges posed by emerging pathogens.
Targeting Cancer with ERV Vaccines
InProTher is developing BreakImmune, an immunotherapy targeting HERVs to create a cancer vaccine (IPT001) that enhances immune responses against solid tumors.